Table 4 COPD disease characteristics in the Ext-SLS cohort and SLS ITT populations, captured at the entry to the SLS.
From: Extending the data collection from a clinical trial: The Extended Salford Lung Study research cohort
Ext-SLS Population (N = 349) | SLS ITT Population (N = 2799) | |
|---|---|---|
Duration of COPD, n (%) | ||
<5 years | 185 (53.0) | 1319 (47.1) |
≥5 to <10 years | 103 (29.5) | 975 (34.8) |
≥10 to <15 year | 31 (8.8) | 321 (11.5) |
≥15 to <20 years | 13 (3.7) | 98 (3.5) |
≥20 to <25 years | 9 (2.6) | 49 (1.8) |
≥25 years | 3 (<1) | 37 (1.3) |
COPD type, n (%) | ||
Chronic bronchitis | 18 (5.2) | 137 (4.9) |
Emphysema | 50 (14.3) | 398 (14.2) |
Chronic bronchitis and emphysema | 7 (2.0) | 37 (1.3) |
Not diagnosed | 274 (78.5) | 2226 (79.5) |
Number of moderate and severe exacerbationsa during the year prior to randomization | ||
0 | 68 (19.5) | 530 (18.9) |
1 | 130 (37.2) | 902 (32.2) |
≥2 | 150 (43.3) | 1367 (48.9) |
Mean (SD) | 1.85 (1.9) | 2.01 (2.0) |
Range | 0–14 | 0–15 |
Number of moderate exacerbations | ||
0 | 74 (21.2) | 568 (20.2) |
≥1 | 275 (78.8) | 2231 (79.7) |
Number of severe exacerbationsan (%) | ||
0 | 332 (95.1) | 2613 (93.4) |
≥1 | 17 (4.9) | 186 (6.6) |
Post-bronchodilator FEV1 (L)b | ||
Mean (SD) | 1.744 (0.6) | 1.619 (0.6) |
Range | 0.43–3.88 | 0.33–4.31 |
Post-bronchodilator percent predicted FEV1 (%)b | ||
Mean (SD) | 63.44 (17.8) | 60.68 (19.1) |
Range | 10.8–111.5 | 10.8–129.1 |
Post-bronchodilator FVC (L)b | ||
Mean (SD) | 3.188 (1.0) | 2.993 (1.0) |
Range | 1.14–6.41 | 0.62–7.06 |
Post-bronchodilator FEV1/FVC (%)b | ||
Mean (SD) | 54.79 (12.4) | 54.52 (13.4) |
Range | 23.6–82.5 | 18.3–98.6 |
GOLD category at baseline, n (%)b | ||
GOLD Grade 0 | 31 (11.1) | 268 (12.2) |
GOLD Grade 1 or 2 | 188 (67.1) | 1293 (58.8) |
GOLD Grade 3 or 4 | 61 (21.8) | 638 (29.0) |
CAT score at baseline, n (%)c | ||
<10 | 50 (14.3) | 286 (10.2) |
≥10 | 299 (85.7) | 2510 (89.8) |
